Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Tryptamines”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,513 records · Page 84Linked to original sources

Differences in monoamine oxidase activity between cultured noradrenergic and cholinergic sympathetic neurons.

Two types of monoamine oxidase activity (MAO-A and MAO-B) help regulate the levels of biogenic amines such as catecholamines and serotonin. Although MAO-A has greater activity toward most catecholamines than MAO-B, no direct experiments have determined the types and levels of MAO activity that are normally expressed in noradrenergic neurons. Noradrenergic neurons from neonatal rat superior cervical ganglia were isolated and cultured under conditions that permit either continued expression of the noradrenergic phenotype or promote a transition to a predominantly cholinergic phenotype. After 14-21 days in vitro, neurons from both types of cultures were assayed for the type and amount of monoamine oxidase activity using tryptamine, a common substrate for both MAO-A and MAO-B. Neurons cultured under noradrenergic conditions expressed sevenfold greater MAO activity than neurons cultured under cholinergic conditions. Essentially all MAO activity in the noradrenergic cultures was inhibited by preincubation with 10(-8)-10(-9) M clorgyline, which indicated that this activity was primarily MAO-A. Cultures grown under cholinergic conditions exhibited 6- to 10-fold lower MAO-A activity and an 8- to 10-fold lower level of catecholamine synthesis from labeled precursors compared to neurons grown under noradrenergic conditions. These results directly demonstrate that high MAO-A activity is expressed in noradrenergic neurons in vitro. The corresponding decreases in both MAO-A specific activity and catecholamine synthesis as neurons become cholinergic in vitro suggest that the expression of the noradrenergic phenotype involves the coordinate regulation of degradative as well as synthetic enzymes involved in catecholamine metabolism.

Animals↗

Effects of melatonin on the photosensitive epilepsy of the baboon, Papio papio.

The acute pharmacological effects of melatonin (5-methoxy-N-acetyl-tryptamine) were evaluated on behaviour and electrographic signs in the photosensitive baboon (Papio papio), including visually evoked potentials VEPs). Doses of 5 and 10 mg/kg i.v. had little effect, contrasting with the enhancement of spontaneous paroxysmal activity and latency of clinical signs elicited by intermittent light stimulation (ILS) produced by the 20 and 50 mg/kg doses. Moreover, a modification of the electrographic pattern of discharge during ILS-induced myoclonic responses was observed. These observations indicate a slight decrease of light sensitivity after melatonin. Only frontal VEPs were modified, with increase in amplitude of their late components for all doses tested. These effects lasted for 2-4 h. The participation of serotoninergic mechanisms involved in melatonin effect and in this model of experimental epilepsy are discussed.

Animals↗

Comparative effects of hallucinogenic drugs on rotational behavior in rats with unilateral 6-hydroxydopamine lesions.

The dopaminergic actions of various hallucinogenic drugs were assessed by examining their effects on turning behavior in rats with unilateral 6-hydroxydopamine lesions of the nigro-striatal pathway. LSD (0.1 and 0.2 mg/kg) produced strong contralateral turning, indicating that it is a potent dopamine receptor agonist, while BOL (5 mg/kg), a non-hallucinogenic congener of LSD, was found to be a weak dopamine receptor agonist. STP (2 and 5 mg/kg) and mescaline (50 and 100 mg/kg) produced significant ipsilateral turning, indicating that these compounds have a moderate dopamine-releasing action. DMT (10 and 20 mg/kg) and 5-M-DMT (0.75 and 1.25 mg/kg) produced weak ipsilateral turning, which was not significantly different from that produced by the nonhallucinogenic compounds tryptamine (40 mg/kg) or scopolamine (0.25 mg/kg). Psilocin (1-20 mg/kg) produced no significant turning in either direction. These data, in conjunction with previous studies, indicate that while inactivation of the brain serotonin system may be a necessary and sufficient condition for hallucinogenesis, the ability to activate dopamine receptors may be an important factor in determining the potency of hallucinogens.

Animals↗

Serotonin receptors in hippocampus and frontal cortex.

The inhibition by various serotonin agonists and antagonists of the binding of 3 nM 3H-d-LSD, 1.7 nM 3H-serotonin and 0.22 nM 3H-spiperone to homogenates of calf hippocampus and frontal cortex was studied. The 50% inhibitory concentration (IC50) for these drugs versus 3H-d-LSD binding had similar values to and correlated with corresponding IC50 values versus 3H-serotonin binding in the hippocampus, suggesting that 3H-LSD and 3H-serotonin label similar sites in this region. In the calf frontal cortex, serotonin revealed a biphasic inhibition against 3H-d-LSD binding and the tryptamines inhibited over a concentration range of 10 000-fold. The IC25 values of various drugs versus 3H-d-LSD binding correlated with the IC50 values versus 3H-serotonin, but did not correlate with the IC50 values versus 3H-spiperone. These data suggest that 3H-d-LSD bound to more than one serotonin site in the calf frontal cortex and that 3H-spiperone bound to a separate serotonergic site. Scatchard analyses of the binding for these three 3H-ligands indicated that in the calf frontal cortex the density of 3H-d-LSD sites was approximately equal to the sum of the densities for 3H-serotonin (S-1 sites) and 3H-spiperone (S-2 sites). Two weeks after serotonin-depleting radiofrequency heat lesions of the midbrain dorsal and median raphe nuclei in rats, both 3H-serotonin and 3H-LSD showed enhanced binding in the hippocampus. These data support previous suggestions that supersensitivity develops specifically in serotonin receptors following afferent denervation.

Animals↗

Imidazole-induced potentiation of the contractile response to various agonists in vascular smooth muscle.

In isolated rabbit aortae, imidazole (10(-4)M) caused a unique nonspecific potentiation of the contractile responses to prostaglandins, norepinephrine, 5-hydroxytryptamine, histamine and potassium only at low concentrations. Imidazole had no effect on the dose-response relationship for Ca2+ in the presence of potassium, 40 mM. Imidazole potentiated contractions in supersensitive strips pretreated with reserpine or with low temperature (5 degrees C) for 5 days. In the presence of theophylline (3 x 10(-4)M), imidazole failed to potentiate the responses to norepinephrine, 5-hydroxy-tryptamine, histamine and potassium, but significantly potentiated responses to prostaglandin E1, E2 and F2 alpha. Imidazole (10(-4)M) significantly decreased the 45Ca uptake of aorta in a Ca-free solution, whereas the drug did not affect 45Ca uptake in a normal solution. These results suggest that imidazole-induced potentiation is related to an increase in Ca2+ permeability and possibly to an additive effect on Ca2+ binding.

Animals↗

Effects of pirenperone and ketanserin on rat prolactin secretion in vivo and in vitro.

Pirenperone, which is chemically related to ketanserin, has been reported to be a selective serotonin2 (5-HT2) antagonist and a specific d-LSD antagonist. We now report that pirenperone markedly stimulates prolactin (PRL) secretion in vivo at low doses and blocks the dopamine (DA)-induced inhibition of PRL release from rat pituitary glands in vitro, suggesting it acts as an antagonist at DA2 receptors in the anterior pituitary gland. Ketanserin, also a purported selective 5-HT2 receptor blocker, has no effect on rat PRL secretion in vivo or in vitro, but at high doses, it inhibits the increase in serum PRL levels produced by the two 5-HT agonists, quipazine and 5-methoxy-N,N-dimethyl-tryptamine (5-MeODMT). It had a weak ability to antagonize the PRL-releasing effect of the 5-HT precursor, 5-hydroxytryptophan. These results suggest that serotonergic stimulation of rat PRL secretion by quipazine and 5-MeODMT may be partially mediated by 5-HT2 receptors. The inability of ketanserin to effectively block the effect of 5-HTP suggests its mechanism of stimulating PRL secretion is more complicated than that of the direct acting agonists.

Animals↗

Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat.

At doses of 5-10 mg kg-1, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (NMPTP) produces in rats acute immobility, retropulsion, straub tail, piloerection, exophthalmos, salivation and clonic movements of the forepaws. It does not produce analgesia as measured by the tail test, nor does it produce permanent motor impairment after chronic or intranigral administration. The acute retropulsion and immobilizing effects can be blocked by methysergide. Administered acutely, NMPTP doubles levels of serotonin in the raphe nucleus and substantia nigra. At the same time, levels of dopamine increase in the caudate nucleus and decrease in the substantia nigra. The NMPTP-induced decrease in dopamine content of the substantia nigra persists in chronically treated rats, but there is no significant decrease in striatal dopamine. After chronic administration of NMPTP, striatal levels of dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were decreased by about 50%. Intranigral administrations of NMPTP (10 micrograms daily for 5 days) failed to produce a 6-hydroxydopamine-like lesion in the nigrostriatal system. These results indicate that NMPTP in the rat does not cause selective destruction of dopaminergic neurons, but it does produce acute tryptamine-like effects.

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine↗

Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (-)[125I]iodocyanopindolol, [3H]mesulergine and [3H]ketanserin.

The pharmacological characteristics of the binding of [3H]8-OH-DPAT ([3H]8-hydroxy-2(di-n-propylamino)tetralin, [125I]CYP ((-)[125I]iodocyanopindolol) (in the presence of 30 microM (-)isoprenaline) and [3H]mesulergine to 5-HT1 recognition sites were studied in rat and pig brain membranes. [3H]8-OH-DPAT bound in rat and pig cortex to the 5-HT1A recognition site characterized by high affinity for 5-CT (5-carboxamido-tryptamine), 8-OH-DPAT, 5-HT (5-hydroxytryptamine, serotonin) and low affinity for pirenperone, ketanserin and mesulergine. [125I]CYP bound in rat but not in pig cortex to the 5-HT1B site which shows high affinity for (-)21-009 (4[3-ter-butyl-amino-2-hydroxy-propoxy]indol-2-carbonic acid isopropyl ester), (+/-)ICYP (3-I-cyanopindolol), 5-HT, RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridon-4-yl]1H-indole) and low affinity for 8-OH-DPAT, mesulergine and pirenperone. [3H]Mesulergine bound in pig choroid plexus and in rat cortex (besides binding to 5-HT2 sites in rat cortex) to the 5-HT1C recognition site characterized by high affinity for metergoline, mesulergine, 5-HT and methergine and low affinity for (-)21-009, ICYP, 8-OH-DPAT and spiroperidol. The pharmacological profile of 5-HT1A sites in rat and pig cortex appears to be identical; 5-HT1C sites in pig choroid plexus and rat cortex show no differences. In contrast, it was not possible to label 5-HT1B sites with [125I]CYP in pig brain membranes indicating that like 5-HT2 receptors, 5-HT1 recognition sites show species differences. The pharmacological profiles of the three 5-HT1 recognition sites are clearly different from one another. Furthermore, the pharmacological profile of each individual 5-HT1 recognition site is also different from that of the 5-HT2 receptors labelled with [3H]ketanserin in rat cortex membranes although some similarities exist between 5-HT2 and 5-HT1C sites. Finally, the beta-adrenoceptor antagonist (-)21-009 which has different affinities for 5-HT1A, 5-HT1B and 5-HT1C recognition sites, yielded triphasic competition curves for [3H]5-HT binding in rat cortex membranes providing evidence that [3H]5-HT labels three distinct 5-HT1 sites in these membranes.

8-Hydroxy-2-(di-n-propylamino)tetralin↗

Solubilization and characterization of the 5-hydroxytryptamine transporter complex from rat cerebral cortical membranes.

The 5-hydroxytryptamine transporter complex from rat cerebral cortical membranes was solubilized with digitonin. The affinity of the solubilized transporter complex for [3H]paroxetine, a very selective and potent inhibitor of 5-hydroxytryptamine uptake, was not affected and remained unchanged when compared with the parent membrane preparation. The solubilization yield of membrane-bound [3H]paroxetine binding sites was 42%. The pharmacological profile of the solubilized transporter complex was similar to that of the intact transporter in membranes of the cerebral cortex, with the exception of tryptamine, which exhibited a 10-fold loss in potency to inhibit [3H]paroxetine binding to the solubilized transporter when compared to membranes. The Stokes radius determined by gel filtration was 7.6 nm. This successful solubilization of the neuronal 5-hydroxytryptamine transporter complex is the starting point for purification of this macromolecular moiety.

Animals↗

Comparison of the actions of serotoninergic agents on human saphenous veins and platelets.

Changes in tension of helical strips from human saphenous veins and reversible aggregation of human platelets were recorded in vitro. Comparison of the activities of 12 serotonin receptor agonists revealed that only 4 of the investigated tryptamine derivatives acted as full agonists on both tissues. 5-Carboxamidotryptamine, a drug with selective affinity for both 5-HT1A and 5-HT1B binding sites, though the most potent agonist on veins, failed to produce platelet aggregation but acted as a weak antagonist of the 5-HT-induced reversible aggregation. The tetralin derivative 8-OH-DPAT, a drug with selective affinity for 5-HT1A binding sites, was a weak partial agonist on veins and completely devoid of any activity on the platelets. The antagonism of 5-HT by spiperone was monophasic on platelets but biphasic on veins. These data are in line with the contention that the 5-HT-induced reversible aggregation of human platelets is initiated by 5-HT2-like recognition sites while the evidence suggests that the contractile response of human saphenous vein to 5-HT reflects activation of both 5-HT2- and 5-HT1-like recognition sites.

Blood Platelets↗

Bradykinin receptor antagonists used to characterize the heterogeneity of bradykinin-induced responses in rat vas deferens.

The application of bradykinin to the isolated, transmurally stimulated rat vas deferens caused two effects: increase of the basal tension of the tissue and potentiation of the magnitude of electrically driven twitches. These bradykinin responses were not evenly distributed along the ductus. The direct contractile action of bradykinin was found to be stronger in the epididymal half of the tissue while the potentiation of the muscle twitches was more pronounced in the prostatic half of the rat ductus. Bradykinin is more potent to potentiate the electrically driven twitches than to act as a postjunctional agonist. Tyr-bradykinin, [Tyr5]bradykinin and [Tyr8]bradykinin exhibited significant differences in the potency ratio to produce each of these responses. [Thi5,8,D-Phe7]bradykinin is a weak postjunctional agonist but was a full agonist to potentiate the electrically induced twitches. Furthermore, this compound antagonized the bradykinin-induced contractions. [Hyp3,Thi5,8,D-Phe7]bradykinin was devoid of agonist activity at either pre- or postjunctional sites; it behaved as a pure antagonist and was more than potent its non-hydroxylated analog. The addition of a D-Arg residue at the amino terminal increased the antagonist potency significantly. The pA2 of D-Arg-[Hyp3,Thi5,8,D-Phe7]bradykinin to antagonize the postjunctional effect of bradykinin was 6.35, a value that differed significantly from the value of 6.93 required to block the prejunctional effect of the peptide. The bradykinin receptor antagonists did not modify significantly the magnitude of the contractile responses caused by angiotensin II, norepinephrine or 5-hydroxy-tryptamine.

Animals↗

5-Hydroxytryptamine stimulates the release of prostacyclin but not thromboxane A2 from isolated rat dental pulp.

The effect of 5-hydroxytryptamine (5-HT) on the release of prostacyclin and thromboxane (TX) A2 from isolated rat dental pulp was evaluated. 5-HT (1-1,000 microM) caused a dose-dependent and marked stimulation of the release of prostacyclin but not TXA2. Of the 5-HT-related indolealkylamines tested, only tryptamine had a similar stimulatory effect while tryptophan and 5-hydroxytryptophan had no effect. Neither histamine (100 microM) nor bradykinin (100 microM) had such an effect. Our results suggest the possible involvement of 5-HT receptors in 5-HT-induced stimulation of prostacyclin production in rat dental pulp.

Animals↗

Receptor-mediated stimulation of aortic prostacyclin release by 5-hydroxytryptamine.

5-Hydroxytryptamine (5-HT) stimulated prostacyclin release, measured by radioimmunoassay as 6-keto-prostaglandin F1 alpha, from rat aorta in a dose-dependent manner (3 X 10(-7)-10(-4) M). A statistically significant stimulation was observed at concentrations higher than 3 X 10(-6) M. Norepinephrine also increased prostacyclin release but only at a high concentration (10(-4) M) and histamine (3 X 10(-5) and 10(-4) M) had no significant effect. Among some structurally 5-HT-related analogues, only tryptamine exhibited a dose-dependent stimulatory effect on prostacyclin release but it was slightly less potent than 5-HT. Tryptophan and 5-hydroxytryptophan had no effects whereas 5-hydroxyindoleacetic acid at 10(-4) M stimulated slightly. Prostacyclin release stimulated by 5-HT was depressed by non-specific 5-HT antagonists, methysergide, mianserin and cyproheptadine. In contrast, a specific 5-HT2 antagonist ketanserin (3 X 10(-7)-10(-5) M) had no antagonistic effect. These results suggest that 5-HT stimulates the release of prostacyclin from rat aorta by interaction with receptors distinct from its 5-HT2 subtype.

Animals↗

Drug-induced penile erections in rats: indications of serotonin1B receptor mediation.

The induction of penile erections by a variety of compounds with a direct or indirect effect on serotonin (5HT) receptors was investigated in rats. L-5-Hydroxy-tryptophan (L-5HTP) induced penile erections when co-administered with nialamide and the peripheral decarboxylase inhibitor benserazide, indicating that the site of action for inducing penile erections is within the central nervous system. Penile erections were also induced by the 5HT uptake inhibitors zimelidine, fluoxetine, citalopram, Org 6997, by the 5HT-releasing agent fenfluramine and by the putative 5-HT1B receptor agonist 1-(3'-chlorophenyl)-piperazine (mCPP). The 5HT1A-agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) did not induce penile erections. The less selective 5HT receptor agonists 5-methoxy-N,N-dimethyl-tryptamine (5MeODMT), 5-methoxytryptamine (5MeOT), dl-lysergic acid diethylamide (LSD) and Ru 24969 were also ineffective. Induction of penile erections by quipazine appeared only when this compound was co-administered with the 5HT2 receptor antagonist pirenperone. Receptor antagonists were tested against penile erections induced by Org 6997. The beta-adrenoceptor antagonists that also have 5HT1 antagonistic properties, (S)-pindolol and dl-propranolol, antagonized Org 6997-induced penile erections but butoxamine and metoprolol did not. Spiperone and pirenperone in doses selective for 5HT1A and 5HT2 receptors respectively were also inactive. Haloperidol, 0.46 mg/kg, partially attenuated penile erections induction. The data are discussed in the light of the hypothesis that penile erections induction by serotonin-mimetic compounds is mediated by 5HT1B receptors in the striatum.

5-Hydroxytryptophan↗

Serotonin involvement in the inhibition of luteinizing hormone (LH) release induced by prostaglandin D2 (PGD2) in castrated male rats.

p-Chlorophenylalanine (PCPA, 320 mg/kg i.p.), an inhibitor of serotonin (5-HT) synthesis, and 5,6-dihydroxy-tryptamine (5,6-DHT, 50 micrograms i.c.v.), a drug toxic to the indoleaminergic system were used to test the involvement of 5-HT in the mediation of the inhibitory effect of prostaglandin D2 (PGD2) on luteinizing hormone (LH) release in castrated male rats. The i.c.v. administration of PGD2 suppressed the episodic LH release characteristic of castrated rats and decreased mean plasma LH levels and mean LH pulse amplitude significantly. Pretreatment with PCPA or 5,6-DHT apparently eliminated the inhibitory effect of PGD2 on LH secretion. These results suggest the possible involvement of a serotonergic mechanism in the mediation of the suppression of LH secretion induced by PGD2 in castrated male rats.

5,6-Dihydroxytryptamine↗

Evidence for ATP as a cotransmitter in dog mesenteric artery.

Contractile responses of the dog mesenteric artery were obtained (after removal of endothelium) to transmural stimulation of the perivascular nerves and to exogenous application of ATP, noradrenaline, dopamine, 5-hydroxy-tryptamine and high potassium solution. The alpha-adrenoceptor antagonists prazosin and phentolamine preferentially reduced the response to noradrenaline and the secondary phase of the biphasic contractile response to nerve stimulation, whilst the addition of alpha, beta-methylene-ATP, which selectively desensitizes P2-purinoceptors, reduced only the contractions to ATP and the portion of the nerve-mediated response which was resistant to the alpha-adrenoceptor antagonists. The responses to nerve stimulation were reduced by the selective P1-purinoceptor agonist 2-chloroadenosine, and its effect was reversed by the P1-purinoceptor antagonist 8-phenyltheophylline. These results suggest that in dog mesenteric artery part of the response to sympathetic nerve stimulation is mediated by ATP acting on P1-purinoceptors on the arterial smooth muscle, and that P1-purinoceptors on the sympathetic nerve terminal can inhibit release of the neurotransmitters.

Adenosine Triphosphate↗

Characterization of the selectivity, specificity and potency of medetomidine as an alpha 2-adrenoceptor agonist.

Medetomidine (4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole) was tested for alpha 2-adrenoceptor agonist activity and compared to several reference agents. In binding studies carried out with rat brain membrane preparations, medetomidine showed high affinity for alpha 2-adrenoceptors, as measured by the displacement of [3H]clonidine (Ki 1.08 nM compared to 1.62, 3.20, 6.22 and 194 nM for detomidine, clonidine, UK 14,304 and xylazine, respectively). The affinity of medetomidine for alpha 1-adrenoceptors, as measured by [3H]prazosin displacement, was much weaker, yielding a relative alpha 2/alpha 1 selectivity ratio of 1620 which is 5-10 times higher than that of the reference compounds. Medetomidine caused a concentration-dependent inhibition of the twitch response in electrically stimulated mouse vas deferens with a pD2 value of 9.0 compared to that of 8.6, 8.5, 8.2 and 7.1 for detomidine, clonidine, UK 14,304 and xylazine, respectively. The effect of medetomidine was antagonized by idazoxan. In anaesthetized rats, medetomidine caused a dose-dependent mydriasis which could be reversed by alpha 2-adrenoceptor blockade. In receptor binding experiments and isolated organs medetomidine had no affinity or effects on beta 1-, beta 2-, H1, H2, 5-HT1, 5-HT2, muscarine, dopamine, tryptamine, GABA, opiate and benzodiazepine receptors. Based on these results, medetomidine can be classified as a potent, selective and specific alpha 2-adrenoceptor agonist.

Adrenergic alpha-Agonists↗

Demonstration of a distinct class of high-affinity binding sites for [3H]norharman [( 3H]beta-carboline) in the rat brain.

Specific binding sites were demonstrated for some beta-carbolines in the rat brain with [3H]norharman as a ligand. The ligand displayed a high affinity for synaptosomal membranes which had been fractionated by a sucrose gradient. The calculated apparent KD value was 1.55 nmol/l and the maximum number of binding sites 148 fmol/mg protein. Displacement studies showed an exclusive specificity for a small group of beta-carbolines but not for the previously described inverse agonists at the benzodiazepine receptor nor for tryptamine and other indoles, as well as pargyline, a monoamine oxidase inhibitor. Further analysis revealed other binding sites for [3H]norharman, with an apparent KD value of 36 nmol/l that are presumably located on mitochondrial membranes. Binding to these sites was also not displaced by pargyline. Pargyline displaced [3H]norharman from a third population of binding sites on mitochondrial membranes with the apparent KD value of 46 nmol/l. These findings could explain the pharmacological effects of norharman and other beta-carbolines in vivo.

Alkaloids↗